Innovation and social impact
In 2020/21, Edinburgh Innovations - which manages the University’s commercialisation activities - marked its fourth consecutive year of record results across several measures.
Edinburgh Innovations helped to launch a record 114 companies founded by staff and students, the first time the total has passed 100 and the highest number of any Russell Group university.
The year included a powerful collection of therapeutics spin-out companies launched from the College of Medicine and Veterinary Medicine, including Resolution Therapeutics, targeting new liver repair treatments, and BioCaptiva, which is developing a device to diagnose cancers from blood biopsies.
Our investments in spinout companies reached another new record, totalling £48 million, as did income from industrial awards and translational awards – many of which involve collaboration with external organisations – which reached £79 million.
Some successes include helping to secure the launch by Evotec and Bristol Myers Squibb of BeLAB1407, with funding of $20 million, to advance drug discovery opportunities and encourage new spinouts from the universities of Edinburgh, Birmingham, Dundee and Nottingham.